The CRAFITY score: A promising prognostic predictor for patients with hepatocellular carcinoma treated with tyrosine kinase inhibitor and immunotherapy combinations-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The CRAFITY score: A promising prognostic predictor for patients with hepatocellular carcinoma treated with tyrosine kinase inhibitor and immunotherapy combinations

Published:2022-08 Issue:2 Volume:77 Page:574-576
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Yang Yi^ORCID,Ouyang Jingzhong^ORCID,Zhou Yanzhao,Zhou Jinxue,Zhao Hong

Publisher

Elsevier BV

Subject

Hepatology

Reference7 articles.

1. Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - Development and validation of the CRAFITY score;Scheiner;J Hepatol,2022

2. Systemic treatment of hepatocellular carcinoma: an EASL position paper;Bruix;J Hepatol,2021

3. Phase Ib study of lenvatinib plus Pembrolizumab in patients with unresectable hepatocellular carcinoma;Finn;J Clin Oncol,2020

4. Advances in immunotherapy for hepatocellular carcinoma;Sangro;Nat Rev Gastroenterol Hepatol,2021

5. Immunotherapies for hepatocellular carcinoma;Llovet;Nat Rev Clin Oncol,2022

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of regorafenib as a first-line agent alone or in combination with an immune checkpoint inhibitor for advanced hepatocellular carcinoma: a retrospective cohort study;Journal of Gastrointestinal Oncology;2024-06

2. The prognostic and antitumor roles of key genes of ferroptosis in liver hepatocellular cancer and stomach adenocarcinoma;Cancer Biomarkers;2024-04-15

3. Alpha-fetoprotein: Past, present, and future;Hepatology Communications;2024-04-12

4. Utility and predictive value of the CRAFITY score in advanced hepatocellular carcinoma treated with transarterial chemoembolization plus tyrosine kinase inhibitors and PD-1 inhibitor;BMC Cancer;2024-02-16

5. Biomarkers and prognostic factors of PD-1/PD-L1 inhibitor-based therapy in patients with advanced hepatocellular carcinoma;Biomarker Research;2024-02-14

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3